Clinical Trials

Inclusion Criteria:

• All subjects will be over age 35.

• Present with gradual progression of PSP-related symptoms and have an informant to provide independent evaluation of functioning.

 All subjects must meet the 2017 Movement Disorder Society clinical criteria for PSP, including any of the clinical presentations of PSP, such as PSP with Richardson’s syndrome, PSP with progressive gait freezing, PSP with predominant parkinsonism,  PSP with predominant frontal presentation, PSP with ocular motor dysfunction, PSP with predominant speech/language disorder and PSP with predominant CBS.

Exclusion Criteria:

• Subjects will be excluded if they do not have the symptoms necessary to fulfill inclusion criteria for PSP.
• Subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded.
• Subjects will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down’s syndrome.
• Subjects will be excluded from the study if MRI is contraindicated (metal in head, cardiac pace maker, etc.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g., chemotherapy).

Eligibility last updated 6/23/23. Questions regarding updates should be directed to the study team contact.